Allarity Therapeutics: Like virtually all other businesses, the defining feature of 2020 for Allarity has been COVID-19 and its response to it. However, we believe the company has been able to deliver on two of its strategic objectives, albeit with delays: to clean up its capital structure and advance its new focused pipe ...
Publicerad: 2021-04-19 11:56 av Edison Investment Research
Allarity Therapeutics: On 26 August 2020 Oncology Venture reported that its PARP inhibitor stenoparib (aka 2X-121) demonstrated activity against COVID-19 in vitro. Following up on this on its 28 August earnings conference call, the company announced that it intends to advance the programme to the clinic as soon as possibl ...
Publicerad: 2020-09-04 15:31 av Edison Investment Research
Allarity Therapeutics: Oncology Venture continues to consolidate the ownership of its pipeline with the purchase of the remaining share of Oncology Venture US held by minority shareholders. This brings the PARP inhibitor 2X-121 fully under ownership of the company (as well as the deprioritised asset 2X-111). The company i ...
Publicerad: 2020-07-14 22:12 av Edison Investment Research
Allarity Therapeutics: Oncology Venture (OV) announced on 8 June 2020 that it acquired the remaining 37% minority stake in its dovitinib asset for SEK36m in stock (25.9m shares issued at SEK1.388 per share). The deal also includes a 10% royalty payment over the next 24 months following the signing (although we do not expe ...
Publicerad: 2020-06-09 23:35 av Edison Investment Research
Allarity Therapeutics: Oncology Venture recently hired new upper management to streamline and focus its operations. This involves a prioritisation of its programmes towards its most attractive assets, which were determined to be the PARP 2X-121, the TKI dovitinib, and the microtubule disruptor Ixempra (ixabepilone). The c ...
Publicerad: 2020-04-16 06:51 av Edison Investment Research
Allarity Therapeutics: Edison justerar upp värdet för forskningsbolaget Oncology Venture i en uppdaterad uppdragsanalys.Analytikern värderar upp bolaget till 1,301 miljarder kronor (1,163) men sänker samtidigt värderingen per aktie till 18,47 kronor (23,13 ) efter emissionen.Datum för uppdragsanalys 12 juni 2019.Analysen ...
Publicerad: 2019-06-12 22:32 av Edison Investment Research